Introduction

Pulsed low-dose CTX therapy has become the most effective approach in improving the clinical outcomes of lupus nephritis (LN) patients. However, variations in CTX therapeutic outcomes in LN patients have not been completely understood.

CTX is an inactive pro-drug that undergoes complex metabolic activation and inactivation reactions. Hydroxylation at the C4 position of CTX, an initial activation step, generates 4-hydroxycyclophosphamide (4OHCTX), and this is mediated by various cytochrome P450 (CYP) enzymes. 4OHCTX is detoxified by glutathione-S-transferase (GSTs) to form 4-glutathionylcyclophosphamide [1].

GSTA1 is involved in CTX metabolism and in vitro studies confirm that GSTA1, among human GSTs, has the highest catalytic activity for GSH conjugation of cyclophosphamide metabolites. CTX response is thought to be associated with a conjugation of aldophosphamide and phosphamide mustard with glutathione through polymorphic glutathione S-transferase GSTA1 [2].

In the present study, we explained the influence of GSTA1 gene polymorphism on CTX therapy in LN patients according to Pharmacokinetics.

Methods and Results

Clinical data and blood samples were collected from patients (n=77) histologically confirmed LN (Classes III-V) in the Nephrology Department of Huashan Hospital affiliated Fudan University. All patients received monthly intravenous CTX (0.5 g/m²) therapy for 6 months. Some patients are not included if (1) they are pregnant or breast-feeding, (2) they had serious chronic heart or haematological or lung disease not due to SLE complication, (3) AST or ALT is exceed 3 times the upper limits of normal, (4) they are taking or used allopurinol, busulphan, chloramphenicol or ciprofloxacin within 2 months as these drugs may restrain CTX metabolism, (5) they are lost to follow up during the period of clinical observation. This study was approved by the Ethics Committee of Fudan University for Clinical Studies. Written informed consent was obtained from all participants.

A complete remission (CR) was defined as a value for urinary protein excretion that was less than 0.3 g per 24 h, with normal urinary sediment and serum albumin (ALB) concentration, and values for both serum creatinine (sCr) and creatinine clearance that were 15% or less above the baseline values. A partial remission (PR) was defined as a value for urinary protein excretion that was 0.3-2.0 g per 24 h, with an ALB concentration of at least 3.0 g/dL, and stable renal function. Complete remission and partial remission were defined as effective remission.

No-remission was defined as a value for urinary protein excretion that remained at or above 3 g per 24 h, or a value of 0.3-2.9 g per 24 h but with an ALB concentration of less than 3.0 g/dL, an increase in the sCr concentration greater than or equal to 0.6 mg/dL (50 μmol/L), or a value for creatinine clearance that was more than 15% above the baseline value, or the discontinuation of treatment due to side effects [3].

The study patients were 37 (25, 47.5) years of age, included 70 females and 7 males, and the remission to CTX therapy occurred in 62 patients (80.5%, 57 females and 7 males). No statistically significant difference about the baseline levels of laboratory parameters was noted between remission group and none-remission group. The values about urinary protein, ALB and serum creatinine (sCr) and creatinine clearance that were 15% or less above the baseline levels of laboratory parameters was noted between remission group and none-remission group.

Abstract

Variations of clinical response of cyclophosphamide (CTX) treatment in lupus nephritis (LN) could still be recognized. LN patients with a GSTA1 mutation (CT heterozygous) had a risk of none-response (P=0.005). Pharmacokinetonics data indicated that patients with a GSTA1 heterozygous variant had a lower exposure to 4-OH-CTX compared to wild-type patients (P=0.023). And clinical efficacy was significantly related to higher exposure to 4-OH-CTX (P=0.038). In conclusion, LN patients with GSTA1 heterozygous genotypes had poor CTX treatment response due to less exposure to activated 4-OH-CTX.

Keywords: Lupus nephritis; Nephrology; Cyclophosphamide; GSTA1; Pharmacokinetics; Pharmacogenomics
On analyzing the single genotypes of GSTA1 to parent compound CTX and active metabolic 4-OH-CTX pharmacokinetics, we found that the exposure to active 4-OH-CTX, not CTX, was significantly affected by GSTA1 variant (P = 0.023, Figure 2A). Patients carrying the GSTA1 heterozygous variant had statistical lower exposure to 4-OH-CTX compared to wild-type patients.

As expected, the remission patients had a significant higher exposure to 4-OH-CTX compared to none-response patients (P = 0.038, Figure 2B). However, pharmacokinetics of pro-drug CTX did not statistically influence therapeutic efficacy in our study.

Table 1: Demographic data of the study patients according to therapeutic response. Data were described as median (inter-quartile range, IQR) for continuous variables or number (frequency) for categorical variables; ALB, serum albumin concentration. No significant differences with respect to the characteristics of study population in baseline were observed between remission group and none-remission group. The values about urinary protein, ALB and serum creatinine in remission group were markedly improved compared to none-remission group after CTX therapy for 6 months. P values were determined using Fisher’s exact test.

| Remission group, N=62 | None-remission group, N=15 | P  |
|-----------------------|---------------------------|----|
| Age (year) 38 (25,47.3) | 30 (22,49) | 0.19 |
| Gender | | 0.42 |
| Female 57 (91.9) | 13 (86.7) |
| Male 5 (8.1) | 2 (13.3) |
| Body surface area(m²) 1.51 (1.43,1.61) | 1.65 (1.45,1.88) | 0.2 |
| Pathology | | 0.9 |
| III 2 | 1 |
| IV 47 | 12 |
| V 2 | 0 |
| III+V 6 | 1 |
| IV+V 5 | 1 |
| Urinary protein (g/24h) | | |
| Pre-treatment 2.66 (1.7,4.82) | 3.74 (2,6.03) | 0.36 |
| Post-treatment 0.35 (0.13,1.24) | 3.66 (1.48,4.46) | 0.0006 |
| ALB (g/L) | | |
| Pre-treatment 29 (24,5,33.3) | 28 (17,29.6) | 0.07 |
| Post-treatment 38(35,40) | 27 (20,30) | 0.0001 |
| Serum creatinine (μmol/L) | | |
| Pre-treatment 71(56,88) | 80(44,237) | 0.12 |
| Post-treatment 63(52,5,72.5) | 73(66,128.3) | 0.01 |

Adverse drug reactions (ADRs) of CTX, such as GI symptoms, myelotoxicity and amenorrhea based on the National Cancer Institute Common Toxicity Criteria (CTC) [6], were observed during 6 months follow-up. Almost 20% patients happened ADRs, whereas no relation to different genotypes of GSTA1 or pharmacokinetic of active 4-OH-CTX.

Discussion

Inter-patient variability with respect to CTX therapy outcomes has not been fully elucidated, especially the interplay between pharmacogenomics, pharmacokinetics and pharmacodynamics of CTX. Our study attempts to explain the influence of pharmacogenomics on CTX therapy in LN patients. We find that patients carrying the GSTA1 CT genotype were much poor responding to CTX therapy compared to wild-type patients.

GSTA1, as the highest catalytic activity for GSH conjugation of CTX, has been reported to detoxify the alkylating cytotoxic drugs by conjugation of glutathione (GSH) [2]. Because of the importance of the GSTA1 enzyme in CTX metabolism, reducing GSTA1 activity toward drug substrates, usually due to polymorphisms [7], can theoretically increase systemic exposure to CTX and improve therapeutic effects. However, studies of GSTA1 gene mutations on treatment efficacy to supporting this speculation are limited. To our knowledge, Carol’s group [8] was the first to report that breast cancer patients homozygous for the GSTA1 allele, had greater overall survival during the first 5 years after diagnosis. Several clinical conditions, particularly
immunological diseases, such as SLE, have been associated with reduced GSH [9], which could hamper conjugation reactions with CTX metabolites. This, to some extent, may explain the discrepancies in reported effects of GST gene polymorphisms on CTX efficacy.

**Figure 2:** The interplay between genotype, pharmacokinetics and clinical efficacy of 4-OH-CTX. **Figure A:** The differences of the median area under the curve (AUC) of 4-hydroxycyclophosphamide (4OHCTX) according to the genotypes in 22 lupus nephritis (LN) patients; GSTA1*A heterozygous variant had statistical lower exposure to 4OHCTX compared to wild-type patients (AUC4OHCTX: 12.8 (9.8, 19.5) vs. 27.5 (18.1, 32.8) h*mg/L, P =0.023). **Figure B:** Association between AUC of 4OHCTX and therapeutic outcome to cyclophosphamide (CTX) treatment in 22 lupus nephritis (LN) patients. Clinical remission was significantly related to higher exposure to 4OHCTX (AUC4OHCTX: 26.5 (18.1, 32.8) vs. 12.8 (6.7, 22.7) h*mg/L, P =0.038).

We focused our hypothesis on modification of CTX pharmacokinetics as the most likely explanation of associations between the GSTA1 CT genotype and worse response to CTX therapy. We sought to identify GSTA1 gene variant factors that altered the disposition of CTX and activate metabolite, 4-OH-CTX. The GSTA1 SNP was significantly correlated with exposure to 4OHCTX, but not CTX. There was still in arguing with the influence of GSTA1 SNPs on the pharmacokinetics of CTX [10-12]. Therefore, more studies are needed to clarify relationships between GSTA1 variants and CTX pharmacokinetics.

Our data further show that changes in the disposition of 4-OHCTX more greatly affect the clinical response to CTX therapy than modifications to the disposition of CTX. 4OHCTX, only active metabolite, is the crucial determinant of delivery of phosphoramide mustard to cells, and measurements of exposure to 4OHCTX may be more predictive of CTX efficacy than measurements of CTX [13].

**References**

1. Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, et al. (2005) Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev 37: 611-703.
2. Dirven HA, van Ommen B, van Bladeren PJ (1994) Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 54: 6215-6220.
3. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, et al. (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343: 1156-1162.
4. Liu J, Xi H, Jiang Y, Feng Z, Hou L, et al. (2015) Association of CYP450 single nucleotide polymorphisms with the efficacy of epirubicin in breast cancer patients. J Thorac Dis 7: 1169-1175.
5. De Jonge ME, Huijtema AD, van Dam SM, Rodenhuis S, Beijnen JH (2005) Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin. Ther Drug Monit 27: 756-765.
6. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, et al. (2000) Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47: 13-47.
7. Ping J, Wang H, Huang M, Liu ZS (2006) Genetic analysis of glutathione S-transferase A1 polymorphism in the Chinese population and the influence of genotype on enzymatic properties. Toxicol Sci 89: 438-443.
8. Sweeney C, Ambrosone CB, Joseph L, Stone A, Hutchins LF, et al. (2003) Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer 103: 810-814.
9. Song W, Yuan J, Zhang Z, Li L, Hu L (2014) Altered glutamate cysteine ligase activity in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Exp Ther Med 8: 195-200.
10. Ekhart C, Dooodeman VD, Rodenhuis S, Smits PH, Beijnen JH, et al. (2008) Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 18: 515-523.
11. Timm R, Kaiser R, Lötsch J, Heider U, Sezer O, et al. (2005) Association between cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J 5: 363-373.
12. Kim IW, Yun HY, Choi B, Han N, Kim MG, et al. (2013) Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation. Eur J Clin Pharmacol 69: 1543-1551.
13. De Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH (2005) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 44: 1135-1164.